H.C. Wainwright analyst Robert Burns raised the firm’s price target on IGM Biosciences to $12 from $7 and keeps a Neutral rating on the shares following the Q4 report. The analyst is factoring in roughly $225M in peak risk-adjusted revenues for imvotamab in autoimmune indications with a 10% probability of approval.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on IGMS:
- Igm Biosciences Is Worried About This – Should You Be Worried Too?
- IGM Biosciences sees FY24 operating expenses $210M-$220M
- IGM Biosciences reports Q4 EPS ($1.01), consensus ($1.03)
- IGM Biosciences Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
- Short Report: Childrenâs Place bears undeterred by Mithaq Capital involvement
Questions or Comments about the article? Write to editor@tipranks.com